#ai-bio

OpenAI’s shift to open‑weight AI after cutting a protein‑design project fuels debate over proprietary research, transparency, and the future of media software valuations.

Explore the risks and realities of AI‑driven animal testing, including unverified claims, “slop” vs. “intentful” AI use, and impacts on biohacking and pharmacology.

DeepMind’s AlphaGenome Atlas maps 9 billion DNA mutations, offering AI‑driven impact scores for non‑coding variants that speed discovery and clinical insight.

OpenAI faces allegations of secretly using private math research in Codex, raising questions about AI data privacy and IP theft.

Explore how AI‑driven drug simulation could revolutionize hair‑loss treatments, from DHT blockers to potential gene‑edited cures—insights into future biotech breakthroughs.

AI‑crafted drug Rentosertib shows unverified 6‑year biological age drop in early trials—can AI‑driven breakthroughs truly reverse aging?

Debate rages on whether GPT‑6 Astra truly hits AGI—examining claims, definitions, and the hype versus real sentience, with a critical eye on biotech promises.

François Chollet revises AGI timeline—now expects 2030, earlier than his 2024 estimate, amid faster AI progress and ARC-AGI benchmarks.

Explore how AI risks and “AI slop” are reshaping Reddit’s moderation and crypto markets, with experts debating control, content quality, and market volatility.

Explore how AI is reshaping healthcare labor, sparking claim denial fears, and fueling market skepticism amid a surge of low‑quality content.